HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christopher R Williams Selected Research

Mechanistic Target of Rapamycin Complex 2

4/2014The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christopher R Williams Research Topics

Disease

26Prostatic Neoplasms (Prostate Cancer)
01/2019 - 02/2002
9Neoplasms (Cancer)
01/2017 - 02/2002
2Urinary Tract Infections (Urinary Tract Infection)
12/2018 - 01/2016
2Urinary Incontinence
01/2016 - 09/2012
2Prostatic Intraepithelial Neoplasia
10/2015 - 01/2012
2Carcinogenesis
01/2012 - 01/2012
2Renal Cell Carcinoma (Grawitz Tumor)
01/2011 - 05/2005
1Sepsis (Septicemia)
12/2018
1Abdominal Obesity
11/2017
1Body Weight (Weight, Body)
11/2017
1Obesity
11/2017
1Aortic Aneurysm (Aneurysm, Aortic)
10/2017
1Hemorrhage
10/2016
1Chronic Obstructive Pulmonary Disease (COPD)
01/2016
1Urachal cancer
01/2015
1Urachal adenocarcinoma
01/2015
1Urinary Bladder Neoplasms (Bladder Cancer)
04/2014
1Pain (Aches)
04/2013
1Hip Fractures (Intertrochanteric Fractures)
04/2013
1Urethral Stricture
04/2013
1Tibial Fractures (Fracture, Tibial)
01/2013
1Urge Urinary Incontinence (Urge Incontinence)
09/2012
1Erectile Dysfunction
09/2012
1Thrombocytopenia (Thrombopenia)
11/2010
1Inflammation (Inflammations)
10/2007
1Necrosis
10/2007
1Kidney Neoplasms (Kidney Cancer)
12/2005
1Renal Insufficiency (Renal Failure)
05/2005
1Glioblastoma (Glioblastoma Multiforme)
02/2002
1Glioma (Gliomas)
02/2002

Drug/Important Bio-Agent (IBA)

3Testosterone (Sustanon)FDA Link
01/2019 - 03/2012
3Catechin (Z 7300)IBA
11/2017 - 10/2015
3TeaIBA
11/2017 - 10/2015
3Biomarkers (Surrogate Marker)IBA
11/2017 - 01/2012
3Protons (Proton)IBA
01/2016 - 03/2012
3CobaltIBA
03/2014 - 01/2012
3AndrogensIBA
03/2014 - 01/2012
2polyphenon EIBA
10/2015 - 01/2012
2Docetaxel (Taxotere)FDA Link
03/2014 - 01/2012
2Dendrimers (Dendrons)IBA
11/2008 - 01/2008
1Indicators and Reagents (Reagents)IBA
11/2017
1Caffeine (No Doz)FDA LinkGeneric
11/2017
1Anti-Bacterial Agents (Antibiotics)IBA
01/2016
1Lapatinib (GW572016)FDA Link
04/2014
1OSI 027IBA
04/2014
1PP242IBA
04/2014
1Mechanistic Target of Rapamycin Complex 1IBA
04/2014
1Mechanistic Target of Rapamycin Complex 2IBA
04/2014
1ErbB Receptors (EGF Receptor)IBA
04/2014
1Analgesics (Analgesic Drugs)IBA
04/2013
1Hormones (Hormone)IBA
09/2012
1Glutamine (L-Glutamine)FDA Link
01/2012
1IsoflavonesIBA
01/2012
1Androgen Receptors (Androgen Receptor)IBA
01/2012
1Proto-Oncogene Proteins c-etsIBA
11/2010
1ChemokinesIBA
04/2010
1Biological ProductsIBA
04/2010
1Poly(amidoamine)IBA
11/2008
1Contrast MediaIBA
01/2008
1Dimethyl Sulfoxide (DMSO)FDA LinkGeneric
10/2007
1Proteins (Proteins, Gene)FDA Link
10/2007
1Heat-Shock Proteins (Heat-Shock Protein)IBA
10/2007
1tanespimycin (17AAG)IBA
10/2007
1Cytosine DeaminaseIBA
02/2002
1AntimetabolitesIBA
02/2002
1Fluorouracil (Carac)FDA LinkGeneric
02/2002
1Antineoplastic Agents (Antineoplastics)IBA
02/2002

Therapy/Procedure

14Proton Therapy
01/2019 - 01/2012
8Radiotherapy
01/2019 - 12/2005
7Therapeutics
01/2016 - 12/2005
3Transurethral Resection of Prostate (TURP)
01/2016 - 04/2013
3Aftercare (After-Treatment)
04/2014 - 03/2012
3Chemoprevention
03/2012 - 01/2012
2Nephrectomy
01/2011 - 05/2005
1Perioperative Period
10/2017
1Cryosurgery
05/2016
1Salvage Therapy
05/2016
1Lymph Node Excision (Lymph Node Dissection)
01/2015
1Cystectomy
01/2015
1Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
04/2014
1Transplantation
01/2013
1Injections
10/2007
1Neoadjuvant Therapy
12/2005
1Drug Therapy (Chemotherapy)
02/2002